Amphastar Pharmaceuticals (AMPH) Operating Income (2016 - 2025)
Historic Operating Income for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $25.3 million.
- Amphastar Pharmaceuticals' Operating Income fell 5561.63% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.9 million, marking a year-over-year decrease of 3001.75%. This contributed to the annual value of $205.4 million for FY2024, which is 428.05% up from last year.
- According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Operating Income is $25.3 million, which was down 5561.63% from $42.2 million recorded in Q2 2025.
- Amphastar Pharmaceuticals' 5-year Operating Income high stood at $72.7 million for Q3 2023, and its period low was $10.3 million during Q1 2021.
- Moreover, its 5-year median value for Operating Income was $36.9 million (2023), whereas its average is $36.0 million.
- In the last 5 years, Amphastar Pharmaceuticals' Operating Income skyrocketed by 74237.58% in 2021 and then crashed by 5561.63% in 2025.
- Over the past 5 years, Amphastar Pharmaceuticals' Operating Income (Quarter) stood at $24.3 million in 2021, then soared by 56.0% to $37.8 million in 2022, then skyrocketed by 42.68% to $54.0 million in 2023, then fell by 16.37% to $45.1 million in 2024, then tumbled by 43.91% to $25.3 million in 2025.
- Its Operating Income was $25.3 million in Q3 2025, compared to $42.2 million in Q2 2025 and $37.3 million in Q1 2025.